SEC Filing Summary for CRISPR Therapeutics AG

This filing details transactions by James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG. On March 14, 2026, Kasinger acquired 6,875 Restricted Stock Units (RSUs) with a post-transaction share count of 20,625. The RSUs are subject to a lock-up agreement and represent contingent rights to Common Shares. On the same date, Kasinger acquired 6,875 Common Shares (transaction code M, acquired code A) with a post-transaction count of 94,690 shares. This acquisition is also noted to be under a lock-up agreement. Subsequently, on March 16, 2026, Kasinger disposed of 3,450 Common Shares (transaction code S, disposed code D) at a price of $48.26 per share, resulting in a post-transaction share count of 91,240. This sale was mandated to cover tax withholding obligations related to RSU vesting, as per the company's RSU Settlement Policy, and is not considered a discretionary trade.